ADCETRIS (brentuximab vedotin)注射液

[Jimin Pharmaceutical Guide] Adcetris is used to treat Hodgkin’s lymphoma and systemic anaplastic lymphoma.

Adcetris is a targeted drug that releases a microtubule inhibitor (MMAE) through the complex formed by ADC and CD30 cells and proteolytic cleavage. MMAE is covalently linked to the antibody to destroy the microtubule network in cancer cells and prevent cancer cell growth until the cancer cells die completely.

In a clinical trial of Adcetris alone for the treatment of lymphoma, a total of 102 patients participated, without a control group, and 73% of the patients relieved the progression of tumors, and these patients responded to treatment for an average of 6.7 months;

In another clinical trial, a total of 58 patients were treated with Adcetris alone, and 86% experienced or completely relieved tumor progression, with an average of 12.6 months.

[Model and Specification] 50mg

[Usage and Dosage] Intravenous drip within 30 minutes, 1.8mg/kg, under the supervision of a doctor.

[Manufacturer] Seattle Genetics.

Adcetris is a C30 antibody gene-targeted drug that has excellent effects on specific types of lymphoma. For more safety information, please consult our customer service WeChat.